title: Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C.
abstract: OBJECTIVE
  To evaluate the assessment and treatment outcomes of a prison hepatitis service.
  
  
  METHODS
  A retrospective, observational cohort study of prison inmates who attended hepatitis clinics from 1996 to 2005 at correctional centres in New South Wales.
  
  
  METHODS
  Inmates who attended the clinics, including a nested case-control series of patients who received antiviral treatment and age- and sex-matched patients who did not receive treatment.
  
  
  METHODS
  Demographic and clinical characteristics of patients who attended the service; correlates of selection for antiviral treatment; and clinical and virological outcomes of treatment.
  
  
  RESULTS
  Of the 1043 inmates who attended the clinics, 851 were men (82%) and 994 (95%) were referred for HCV infection; the mean age for this group was 33 years (range, 18-74 years). In the case-control series (185 treated and 186 untreated patients), selection for treatment was not biased by culturally and linguistically diverse background, current methadone treatment or psychiatric status. In the treated group, 76 of 138 genotyped patients had a genotype that is predictive of favourable treatment response, and a small minority of those with available liver biopsy results had established cirrhosis (7/119 patients). Of treated patients for whom complete follow-up data were available, 55% achieved sustained virological response and 100% adhered to therapy. In addition, treatment episodes were not especially complicated.
  
  
  CONCLUSIONS
  Although the prison population has high rates of injecting drug use and poor mental health, imprisonment offers an opportunity for assessment and treatment of chronic HCV infection.
authors.affiliation: Blood Borne Viruses and Sexual Assault Services, Population Health, Justice Health, Sydney, NSW, Australia.
authors.forename: Leng
authors.initials: L
authors.lastname: Boonwaat
authors.forename: Paul S
authors.initials: PS
authors.lastname: Haber
authors.forename: Michael H
authors.initials: MH
authors.lastname: Levy
authors.forename: Andrew R
authors.initials: AR
authors.lastname: Lloyd
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D015331:Cohort Studies; D005260:Female; D005838:Genotype; D006302:Health Services Research; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D009517:New South Wales; D017063:Outcome Assessment, Health Care; D011329:Prisoners / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D000998:Antiviral Agents